Ocular Therapeutix Inc
NASDAQ:OCUL
Ocular Therapeutix Inc
NASDAQ:OCUL
Price:
6.24 USD
-0.79%
Updated:
May 21, 2024
Ocular Therapeutix Inc
Cash from Operating Activities
|
Ocular Therapeutix Inc
Cash from Operating Activities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Ocular Therapeutix Inc
NASDAQ:OCUL
|
Cash from Operating Activities
-$84.2m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-20%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$23.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$13.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8.6B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$14.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$3.7B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
See Also
What is Ocular Therapeutix Inc's Cash from Operating Activities?
Cash from Operating Activities
-84.2m
USD
-84.2m
USD
Based on the financial report for Mar 31, 2024, Ocular Therapeutix Inc's Cash from Operating Activities amounts to -84.2m USD.
What is Ocular Therapeutix Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-20%
-20%
Over the last year, the Cash from Operating Activities growth was -38%. The average annual Cash from Operating Activities growth rates for Ocular Therapeutix Inc have been -17% over the past three years , -8% over the past five years , and -20% over the past ten years .
You don't have any saved screeners yet
